Sommer Lloyd
Family · Towson, MDNPI 1700476272
Payments from drug & device makers
Across 153 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$284
- Sanofi-aventis U.S. LLC$239
- AbbVie$218
- AstraZeneca$212
- Radius Health, Inc.$207
- Corcept Therapeutics$160
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,088100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $284 |
| Sanofi-aventis U.S. LLC | 11 | $239 |
| AbbVie | 13 | $218 |
| AstraZeneca(2 entities) | 12 | $212 |
| Radius Health, Inc. | 8 | $207 |
| Corcept Therapeutics | 8 | $160 |
| Insulet Corporation | 7 | $146 |
| Amneal Pharmaceuticals LLC | 6 | $128 |
| Amgen | 6 | $126 |
| Boehringer Ingelheim | 7 | $125 |
| Lilly USA, LLC | 6 | $114 |
| Bayer | 6 | $111 |
| Cequr Corporation | 3 | $107 |
| Novartis | 5 | $106 |
| Xeris Pharmaceuticals, Inc. | 5 | $98 |
| Tandem Diabetes Care, Inc. | 3 | $66 |
| Embecta Corp. | 2 | $64 |
| Kyowa Kirin, Inc. | 3 | $58 |
| IBSA Pharma Inc. | 3 | $54 |
| Lifescan, Inc. | 3 | $52 |
| Mannkind Corporation | 3 | $45 |
| Zealand Pharma US, Inc. | 2 | $42 |
| BETA Bionics, Inc. | 1 | $34 |
| Recordati_rare_diseases_inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| BD | 1 | $29 |
| Almatica Pharma LLC | 1 | $28 |
| Averitas Pharma Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Nevro Corp. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Medtronic | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
How this compares
$3,088 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $157,952 |
| JardianceEmpagliflozin | 112 | $148,868 |
| TrulicityDulaglutide | 29 | $64,037 |
| MounjaroTirzepatide | 28 | $53,759 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $37,870 |
| JanuviaSitagliptin Phosphate | 49 | $29,636 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $25,804 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $20,420 |
| FarxigaDapagliflozin Propanediol | 61 | $18,910 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $18,894 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $18,860 |
| Humalog Kwikpen U-100Insulin Lispro | 30 | $8,939 |
| Novolog FlexpenInsulin Aspart | 21 | $7,702 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 66 | $7,648 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 14 | $6,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $284 | $160,57893 claims |
| Boehringer IngelheimJardiance | $125 | $148,868112 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $114 | $117,79657 claims |
| AstraZenecaFarxiga | $212 | $18,91061 claims |
| AbbVieSynthroid | $218 | $4,64555 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $128 | $98695 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,843 family providers in Maryland.
Other family in Towson
- Temitope FoworaTowson$17K
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.